Review
doi: 10.1002/jso.25302.
Epub 2018 Nov 27.
Melanoma of unknown primary
Affiliations
- PMID: 30481368
- DOI: 10.1002/jso.25302
Item in Clipboard
Review
Melanoma of unknown primary
J Surg Oncol.
2019 Jan.
Abstract
Formally described in the 1960s, melanoma of unknown primary (MUP) is characterized by the finding of metastatic melanoma within the lymph nodes, subcutaneous tissues, and other distant sites without an evident primary lesion. The most likely hypothesis of its etiology is an immune-mediated regression of the primary after metastasis has occurred. In addition, patients with MUP appear to have equivalent or better outcomes compared with patients with known primaries of a similar stage.
Keywords: malignant melanoma; melanoma occult primary; melanoma regression; unknown primary.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.Ann Surg Oncol. 2014 Sep;21(9):3108-16. doi: 10.1245/s10434-014-3679-5. Epub 2014 May 7. Ann Surg Oncol. 2014. PMID: 24802907 Clinical Trial.
-
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.J Immunother Cancer. 2022 Jan;10(1):e004310. doi: 10.1136/jitc-2021-004310. J Immunother Cancer. 2022. PMID: 35074904 Free PMC article. Clinical Trial.
-
Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.Melanoma Res. 2005 Feb;15(1):77-82. doi: 10.1097/00008390-200502000-00013. Melanoma Res. 2005. PMID: 15714125 Review.
-
Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site.J Plast Surg Hand Surg. 2023 Feb-Dec;57(1-6):109-114. doi: 10.1080/2000656X.2021.2010739. Epub 2021 Dec 8. J Plast Surg Hand Surg. 2023. PMID: 34878354
-
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.Oncology. 2017;93(4):249-258. doi: 10.1159/000478050. Epub 2017 Jul 27. Oncology. 2017. PMID: 28746931 Free PMC article. Review.
Cited by
-
CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.Cells. 2024 Jan 26;13(3):240. doi: 10.3390/cells13030240. Cells. 2024. PMID: 38334632 Free PMC article. Review.
-
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.Cancer Immunol Immunother. 2021 Nov;70(11):3123-3135. doi: 10.1007/s00262-021-02871-1. Epub 2021 Mar 27. Cancer Immunol Immunother. 2021. PMID: 33774697 Free PMC article.
-
Isolated melanoma metastasis in a patient with large congenital nevus without detectable primary melanoma: a case report and review of literature.Front Med (Lausanne). 2024 Oct 15;11:1427982. doi: 10.3389/fmed.2024.1427982. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39473498 Free PMC article.
-
Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis.Therap Adv Gastroenterol. 2021 Feb 24;14:1756284821989559. doi: 10.1177/1756284821989559. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 33717209 Free PMC article.
-
Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results.Oncoimmunology. 2019 Oct 21;8(12):e1677139. doi: 10.1080/2162402X.2019.1677139. eCollection 2019. Oncoimmunology. 2019. PMID: 31741779 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
